Hypoglycaemia is a frequent adverse effect of treatment of diabetes mellitus with insulin and
sulphonylureas. Fear of hypoglycaemia alters self-management of diabetes mellitus and …

Hypoglycemia is an important complication of glucose-lowering therapy in patients with
diabetes mellitus. Attempts made at intensive glycemic control invariably increases the risk …

Importance Hypoglycemia, a serious risk for insulin-treated patients with type 2 diabetes,
negatively affects glycemic control. Objective To test whether treatment with basal insulin …

Aims To conduct a patient‐level meta‐analysis of the EDITION 1, 2 and 3 studies, which
compared the efficacy and safety of new insulin glargine 300 U/ml (G la‐300) with insulin …

With their novel, insulin‐independent mechanism, sodium‐glucose cotransporter‐2 (SGLT2)
inhibitors are a major turning point in the management of type 2 diabetes mellitus. At …

Importance Hypoglycemia, common in patients with type 1 diabetes, is a major barrier to
achieving good glycemic control. Severe hypoglycemia can lead to coma or death. Objective …

Objective To collate and evaluate the current literature reporting the prevalence and
incidence of hypoglycaemia in population based studies of type 2 diabetes. Research …

OBJECTIVE To compare ultra-long-acting insulin degludec with glargine for efficacy and
safety in insulin-naive patients with type 2 diabetes inadequately controlled with oral …

Insulin degludec (IDeg) is a new-generation basal insulin with an ultra-long duration of
action. To date, a large number of studies have been conducted to investigate the …

The primary cause of hypoglycaemia in Type 2 diabetes is diabetes medication—in
particular, those which raise insulin levels independently of blood glucose, such as …